Eikon Therapeutics, Inc. (EIKN)
| Market Cap | 408.40M |
| Revenue (ttm) | n/a |
| Net Income | -322.16M |
| EPS | -13.72 |
| Shares Out | 54.17M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 657,560 |
| Open | 7.01 |
| Previous Close | 7.01 |
| Day's Range | 7.01 - 7.69 |
| 52-Week Range | 6.45 - 17.40 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 24.60 (+226.26%) |
| Est. Earnings | Nov 6, 2026 |
About EIKN
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent W... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for EIKN stock is "Buy." The 12-month stock price target is $24.6, which is an increase of 226.26% from the latest price.
News
Eikon Therapeutics submits EIK1006 IND application to FDA
Eikon Therapeutics (EIKN) announced the submission of an Investigational New Drug, or IND, application to the FDA to evaluate EIK1006 for the treatment of advanced metastatic prostate cancer. EIK1006 ...
Eikon Therapeutics Submits IND for Novel Androgen Receptor Antagonist EIK1006 in Prostate Cancer
MILLBRAE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The conference highlighted robust clinical progress across multiple oncology programs, including promising efficacy and safety data for EIK-1001 and highly selective PARP1 inhibitors. Financially, the company maintains a strong cash position to support ongoing and expanding clinical trials.
Eikon Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Four clinical-stage drug candidates are advancing, including two highly selective PARP1 inhibitors with reduced toxicity and a TLR7/8 agonist in late-stage trials. Proprietary imaging technology accelerates drug discovery and supports expansion into new therapeutic areas. Cash reserves of $531.2 million support ongoing studies.
Eikon Therapeutics appoints Ching-Pin Chang as chief scientific officer
Eikon Therapeutics (EIKN) announced the appointment of Ching-Pin Chang as executive VP and chief scientific officer. Chang joins Eikon from Bristol Myers (BMY), where he most recently served as VP,…
Eikon Therapeutics Appoints Ching-Pin Chang, M.D., Ph.D. as Executive Vice President and Chief Scientific Officer
MILLBRAE, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to ...
Eikon Therapeutics to Participate in Investor Conferences in September 2026
MILLBRAE, Calif., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Transcript: KOL event
PARP1-selective inhibitors are positioned to address the hematologic toxicity of first-gen PARP inhibitors, enabling higher dosing, longer treatment, and more combination options. Eikon's clinical programs show promising early safety and efficacy, with key data to be presented at ESMO. Werner helicase inhibitors offer a new approach for MSI tumors, emphasizing disease control and tolerability.
Eikon Therapeutics to Participate in KOL Event on Therapeutic Use of PARP Inhibitors in Oncology Hosted by Cantor Fitzgerald
Chairman and Chief Executive Officer, Roger M. Perlmutter, M.D., Ph.D., will participate in a key opinion leader (KOL) event on Thursday, August 20, 2026
Eikon Therapeutics reports Q2 EPS ($1.63), consensus ($1.46)
“The second quarter saw meaningful acceleration of Eikon’s most important clinical programs, leading to acceptance of seven abstracts, related to all four of our current clinical candidates, for prese...
Eikon Therapeutics price target lowered to $4 from $5 at Wedbush
Wedbush analyst Robert Driscoll lowered the firm’s price target on Eikon Therapeutics (EIKN) to $4 from $5 and keeps an Underperform rating on the shares. The firm notes the company…
Eikon Therapeutics Slides: Investor presentation
Eikon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on August 14, 2026.
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
MILLBRAE, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Quarterly report: Q2 2026
Eikon Therapeutics has published its Q2 2026 quarterly earnings report on August 13, 2026.
Eikon Therapeutics Earnings release: Q2 2026
Eikon Therapeutics released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Eikon Therapeutics announces dose selection for TeLuRide-006 trial
Eikon Therapeutics (EIKN) announced the selection of a dose of 0.60 mg/m2 that will be employed in future for all patients randomized to receive EIK1001 in the TeLuRide-006 trial. This…
Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board
MILLBRAE, Calif., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics Slides: Company presentation
Eikon Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Eikon Therapeutics doses first patient in TeLuRide-008 study
Eikon Therapeutics (EIKN) announced that the first patient has been dosed in TeLuRide-008, a Phase 2/3 registrational study evaluating EIK1001 in combination with pembrolizumab and histology-appropria...
Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer
MILLBRAE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (Eikon), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to add...
Eikon Therapeutics Announces Seven Abstracts Accepted for Presentation at the 2026 European Society of Medical Oncology (ESMO) Congress
Presentations to cover updates across Eikon's clinical pipeline including: Updated data from TeLuRide-005, an ongoing Phase 2 trial of EIK1001, a TLR7/8 dual agonist, plus pembrolizumab and chemother...
Eikon Therapeutics to be added to Russell 3000 Index
Eikon Therapeutics (EIKN) announced that it will be added to the broad-market Russell 3000 Index following the annual reconstitution, effective after the U.S. market closes on June 26. Published first...
Eikon Therapeutics to Join the Russell 3000® Index
Addition reflects Eikon's progress as a publicly traded company and increasing visibility within the investment community Addition reflects Eikon's progress as a publicly traded company and increasing...
Eikon Therapeutics Announces the Appointment of Ma. Fatima D. Francisco to its Board of Directors
MILLBRAE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to a...
Eikon Therapeutics price target lowered to $32 from $34 at BofA
BofA lowered the firm’s price target on Eikon Therapeutics (EIKN) to $32 from $34 and keeps a Buy rating on the shares. Eikon’s Q1 report was “relatively quiet but nonetheless…